Header Logo

Connection

DOV KADMON to Humans

Back to Details
This is a "connection" page, showing publications DOV KADMON has written about Humans.
DOV KADMON
Connection Strength
0.185
Humans
  1. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82.
    View in: PubMed
    Score: 0.009
  2. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
    View in: PubMed
    Score: 0.008
  3. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer. 2007 Dec 15; 110(12):2628-39.
    View in: PubMed
    Score: 0.007
  4. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
    View in: PubMed
    Score: 0.007
  5. Long-term benefits of elective radiotherapy after prostatectomy for patients with positive surgical margins. J Urol. 2006 Jun; 175(6):2097-101; discussion 2101-2.
    View in: PubMed
    Score: 0.007
  6. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
    View in: PubMed
    Score: 0.006
  7. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol. 2005 Jun; 173(6):1923-5.
    View in: PubMed
    Score: 0.006
  8. Comparison of peritoneal interposition flaps and sealants for prevention of lymphocele after robotic radical prostatectomy and pelvic lymph node dissection: a systematic review, meta-analysis, Bayesian network meta-analysis, and meta-regression. J Robot Surg. 2024 Apr 17; 18(1):177.
    View in: PubMed
    Score: 0.006
  9. Oncologic Outcome of the Extent of Pelvic Lymph Node Dissection During Radical Prostatectomy: A Systematic Review, Meta-analysis, and Network Analysis. Eur Urol Focus. 2024 Mar; 10(2):234-241.
    View in: PubMed
    Score: 0.006
  10. In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther. 2001 May; 1(3):481-95.
    View in: PubMed
    Score: 0.005
  11. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol. 2000 Nov 15; 18(22):3804-8.
    View in: PubMed
    Score: 0.004
  12. Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy. Clin Cancer Res. 2000 Oct; 6(10):3845-9.
    View in: PubMed
    Score: 0.004
  13. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol. 2000 Jul; 31(7):866-70.
    View in: PubMed
    Score: 0.004
  14. Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene. World J Urol. 2000 Apr; 18(2):125-9.
    View in: PubMed
    Score: 0.004
  15. Beyond prostate specific antigen--markers for prostate cancer for the 21st Century. J Urol. 2000 Mar; 163(3):828.
    View in: PubMed
    Score: 0.004
  16. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol. 2000 Jan; 18(1):116-21.
    View in: PubMed
    Score: 0.004
  17. Solitary pulmonary metastasis from prostate cancer. J Urol. 1999 Dec; 162(6):2102.
    View in: PubMed
    Score: 0.004
  18. Histologic features of stromogenic carcinoma of the prostate (carcinomas with reactive stroma grade 3). Hum Pathol. 2017 05; 63:202-211.
    View in: PubMed
    Score: 0.003
  19. Intracranial metastases as the first manifestation of prostate cancer. Urology. 1996 Nov; 48(5):789-93.
    View in: PubMed
    Score: 0.003
  20. Pitfalls in interpreting prostate specific antigen velocity. J Urol. 1996 May; 155(5):1655-7.
    View in: PubMed
    Score: 0.003
  21. Transitional cell carcinoma in a tuberculous kidney: case report and review of the literature. J Urol. 1994 Apr; 151(4):989-91.
    View in: PubMed
    Score: 0.003
  22. Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11.
    View in: PubMed
    Score: 0.003
  23. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs. 2014 Apr; 32(2):235-242.
    View in: PubMed
    Score: 0.003
  24. Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO). J Cell Biochem Suppl. 1992; 16H:122-7.
    View in: PubMed
    Score: 0.002
  25. BCG and the treatment of superficial bladder cancer. DICP. 1991 Dec; 25(12):1355-67.
    View in: PubMed
    Score: 0.002
  26. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol. 1991 Aug; 146(2):358-61.
    View in: PubMed
    Score: 0.002
  27. Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol. 2011 Jan; 178(1):79-87.
    View in: PubMed
    Score: 0.002
  28. Imaging prostate derived tumors with PET and N-(3-[18F]fluoropropyl)putrescine. Int J Rad Appl Instrum B. 1990; 17(6):525-32.
    View in: PubMed
    Score: 0.002
  29. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis. 2010 Mar; 13(1):6-11.
    View in: PubMed
    Score: 0.002
  30. The role of transrectal ultrasonography in the diagnosis and management of prostatic and seminal vesicle cysts. J Urol. 1989 May; 141(5):1206-9.
    View in: PubMed
    Score: 0.002
  31. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7593-603.
    View in: PubMed
    Score: 0.002
  32. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res. 2008 Feb 01; 68(3):731-9.
    View in: PubMed
    Score: 0.002
  33. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol. 2007 Nov; 38(11):1611-20.
    View in: PubMed
    Score: 0.002
  34. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol. 2007 Nov; 38(11):1688-95.
    View in: PubMed
    Score: 0.002
  35. Preliminary report of the effect of high-dose adjuvant intensity modulated radiation therapy on the sural nerve graft for cavernosal nerve sacrifice after radical prostatectomy. Am J Clin Oncol. 2007 Aug; 30(4):395-400.
    View in: PubMed
    Score: 0.002
  36. Percutaneous drainage of prostatic abscesses. J Urol. 1986 Jun; 135(6):1259-60.
    View in: PubMed
    Score: 0.002
  37. Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat. 2006 Feb; 5(1):23-36.
    View in: PubMed
    Score: 0.002
  38. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther. 2006 Jan; 5(1):78-83.
    View in: PubMed
    Score: 0.002
  39. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur Urol. 2005 Jul; 48(1):153-61.
    View in: PubMed
    Score: 0.002
  40. Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer. Urology. 2005 Jan; 65(1):131-5.
    View in: PubMed
    Score: 0.001
  41. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8(2):108-18.
    View in: PubMed
    Score: 0.001
  42. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol. 2004 Sep; 172(3):900-4.
    View in: PubMed
    Score: 0.001
  43. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71.
    View in: PubMed
    Score: 0.001
  44. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol. 2004 May; 171(5):1850-4.
    View in: PubMed
    Score: 0.001
  45. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology. 2004 May; 63(5):905-10; discussion 910-1.
    View in: PubMed
    Score: 0.001
  46. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
    View in: PubMed
    Score: 0.001
  47. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol. 2004 Mar; 171(3):1089-92.
    View in: PubMed
    Score: 0.001
  48. Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. J Urol. 2004 Jan; 171(1):204-9.
    View in: PubMed
    Score: 0.001
  49. Therapeutic targets for metastatic prostate cancer. Curr Drug Targets. 2003 Apr; 4(3):251-61.
    View in: PubMed
    Score: 0.001
  50. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol. 2002 Oct; 168(4 Pt 1):1589-96.
    View in: PubMed
    Score: 0.001
  51. Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile function. Int J Radiat Oncol Biol Phys. 2002 Sep 01; 54(1):101-6.
    View in: PubMed
    Score: 0.001
  52. Gene therapy for prostate cancer. Expert Rev Anticancer Ther. 2002 Jun; 2(3):309-21.
    View in: PubMed
    Score: 0.001
  53. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol. 2002 May; 167(5):2105-8.
    View in: PubMed
    Score: 0.001
  54. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5):458-66.
    View in: PubMed
    Score: 0.001
  55. Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up. Urology. 2001 Dec; 58(6):983-7.
    View in: PubMed
    Score: 0.001
  56. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):605-13.
    View in: PubMed
    Score: 0.001
  57. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67.
    View in: PubMed
    Score: 0.001
  58. Bilateral nerve graft during radical retropubic prostatectomy: 1-year followup. J Urol. 2001 Jun; 165(6 Pt 1):1950-6.
    View in: PubMed
    Score: 0.001
  59. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001 May; 165(5):1554-9.
    View in: PubMed
    Score: 0.001
  60. Interposition sural nerve grafting during radical retropubic prostatectomy. Urology. 2001 Feb; 57(2):211-6.
    View in: PubMed
    Score: 0.001
  61. Gene therapy for prostate cancer. Urology. 2001 Jan; 57(1):8-16.
    View in: PubMed
    Score: 0.001
  62. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol. 2000 Jun; 163(6):1747-50.
    View in: PubMed
    Score: 0.001
  63. Unilocular retroperitoneal cyst of mesothelial origin presenting as a renal mass. Arch Pathol Lab Med. 2000 May; 124(5):766-9.
    View in: PubMed
    Score: 0.001
  64. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1998 Aug; 52(2):195-201; discussion 201-2.
    View in: PubMed
    Score: 0.001
  65. A c-rasHa mutation in the metastasis of a human papillomavirus (HPV)-18 positive penile squamous cell carcinoma suggests a cooperative effect between HPV-18 and c-rasHa activation in malignant progression. Cancer. 1998 Jul 01; 83(1):122-9.
    View in: PubMed
    Score: 0.001
  66. [Multiple giant hepatic hemangiomas]. Harefuah. 1976 May 16; 90(10):470-3.
    View in: PubMed
    Score: 0.001
  67. Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab Invest. 1996 Apr; 74(4):747-60.
    View in: PubMed
    Score: 0.001
  68. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 1995 Mar; 45(3):491-7.
    View in: PubMed
    Score: 0.001
  69. Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J Urol. 1995; 13(6):324-8.
    View in: PubMed
    Score: 0.001
  70. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol. 1993 Jan; 24(1):4-9.
    View in: PubMed
    Score: 0.001
  71. Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl. 1992; 16H:54-61.
    View in: PubMed
    Score: 0.001
  72. N-3-[18F]fluoropropylputrescine as potential PET imaging agent for prostate and prostate derived tumors. J Nucl Med. 1989 Jul; 30(7):1205-10.
    View in: PubMed
    Score: 0.001
  73. Regression of metastatic renal cell carcinoma: a case report and literature review. J Urol. 1986 May; 135(5):1005-7.
    View in: PubMed
    Score: 0.000
  74. Immunotherapy of superficial bladder cancer. J Urol. 1982 Nov; 128(5):891-4.
    View in: PubMed
    Score: 0.000
  75. Prostatic cancer, acid phosphatase, creatine kinase-BB and race: a prospective study. J Urol. 1982 Oct; 128(4):735-8.
    View in: PubMed
    Score: 0.000
  76. Effect of mini-dose heparin on lymphocele formation following extraperitoneal pelvic lymphadenectomy. J Urol. 1980 Jun; 123(6):890-2.
    View in: PubMed
    Score: 0.000
  77. Surgical considerations in treatment of intraductal carcinoma of the prostate. J Urol. 1978 Aug; 120(2):259-61.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.